Evaluation of the effect of L-Carnitine on patients with moderate to severe condition of Covid-19 ?admitted to critical care unit
Phase 3
Recruiting
- Conditions
- With Quid-19 with moderate disease severity.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20141209020258N165
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
Suffering Covid-19 without intubation
Apache less than 25
28 to 75 years
Absence of acute asthma
Absence of acute pulmonary hemorrhage
Absence of lung tumor
Absence of untreated pneumothorax
Do not take anticoagulants (coumadin group such as warfarin)
No history of kidney or liver disease
No diabetes (because of the risk of hypoglycemia)
No history of seizures
Exclusion Criteria
Death
Patient dissatisfaction with attending the study for any reason
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intravenous blood gas samples. Timepoint: Daily. Method of measurement: Intravenous blood samples.;Disease severity. Timepoint: Daily. Method of measurement: Checklist Apache II.;Length of hospital stay. Timepoint: End of study. Method of measurement: Patient file.;Mortality. Timepoint: End of study. Method of measurement: Patient file.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie L-Carnitine's potential therapeutic effects on SARS-CoV-2 viral replication and mitochondrial dysfunction in severe COVID-19 patients?
How does L-Carnitine compare to standard-of-care treatments like remdesivir and corticosteroids in reducing ICU mortality for moderate-to-severe COVID-19?
Are there specific biomarkers such as lactate dehydrogenase (LDH) or C-reactive protein (CRP) that predict L-Carnitine response in critically ill COVID-19 patients?
What are the potential adverse events associated with L-Carnitine administration in ICU settings and how do they compare to tocilizumab-related risks?
How does L-Carnitine's anti-inflammatory and antioxidant properties compare to other mitochondrial modulators like NAC in treating cytokine storm in severe SARS-CoV-2 infections?